Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Receivables (2022 - 2024)

Avidity Biosciences (RNA) has disclosed Receivables for 3 consecutive years, with $9.4 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Receivables rose 754.93% year-over-year to $9.4 million, compared with a TTM value of $9.4 million through Dec 2024, up 754.93%, and an annual FY2024 reading of $9.4 million, up 754.93% over the prior year.
  • Receivables was $9.4 million for Q4 2024 at Avidity Biosciences, up from $1.6 million in the prior quarter.
  • Across five years, Receivables topped out at $9.4 million in Q4 2024 and bottomed at $1.1 million in Q4 2023.
  • Average Receivables over 3 years is $3.1 million, with a median of $1.6 million recorded in 2024.
  • The sharpest move saw Receivables tumbled 53.26% in 2023, then skyrocketed 754.93% in 2024.
  • Year by year, Receivables stood at $2.4 million in 2022, then crashed by 53.26% to $1.1 million in 2023, then surged by 754.93% to $9.4 million in 2024.
  • Business Quant data shows Receivables for RNA at $9.4 million in Q4 2024, $1.6 million in Q1 2024, and $1.1 million in Q4 2023.